PALB2 and pancreatic neoplasm: This findings suggest that gemcitabine plus cisplatin may be effective for BRCA1/2 or PALB2 mutated pancreatic cancer, and the addition of veliparib to gemcitabine/cisplatin chemotherapy may be too toxic [41,42].